Prostate Cancer Foundation 2018 Scientific Retreat

Prostate Cancer Foundation 2018 Scientific Retreat

INTERVIEW WITH ANDREA MIYAHIRA
The Prostate Cancer Foundation: A Discussion with Andrea Miyahira

VIEW ALL PCF VIDEOS

Prostate Cancer Foundation 2018 Scientific Retreat

Prostate Cancer Foundation 2018 Scientific Retreat

INTERVIEW WITH KENNETH PIENTA
The Process of Metastasis in Prostate Cancer

VIEW ALL PCF VIDEOS

European Society for Medical Oncology 2018 Congress

European Society for Medical Oncology 2018 Congress

INTERVIEW WITH FRED SAAD
A Renewed Analysis of ERA 223

VIEW ALL ESMO VIDEOS

Videos
State-of-the-industry video lectures by leading urology experts
Latest Videos
Featured Videos

TAIPEI, TAIWAN (UroToday.com) - Introduction and Objectives: To analyze oncological outcomes after radical prostatectomy for high-risk prostate cancers.


Methods: From November 1996 to January 2014, all D’Amico high-risk prostate cancers with radical prostatectomy performed were included. Pathological and oncological outcomes were analyzed.

wceResults: 92 patients with 24 open, 7 laparosocopic, and 61 robotic prostatectomies were included. Pre-operative mean PSA was 25.4 + / - 23 ng/ml, and 48.9% had palpable prostate nodule. 57.6% patients had pre-operative Gleason score 8–10. Pathological staging showed 25.0% T2c, 31.5% T3a and 25.0% T3b. Pathological N1 was seen in 8.7% patients. There were 35.2% Gleason 7 and 34.3% Gleason 8–10. Positive surgical margin rate was 34.8%. There was a trend towards lower positive surgical margins in robotic group (29.5%) compared with laparoscopic (42.9%) and open (45.8%) groups. Excluding 13 patients with early post-operative androgen deprivation therapy (ADT), 71.8% had undetectable PSA nadir, and there was no difference comparing different surgical approaches. At a median follow-up of 4.5 (range 0.1–17.5) years, 18.2% had biochemical recurrence, 11.7% had adjuvant radiotherapy, 10.4% had salvage radio-therapy, 14.4% had early ADT, 22.2% had late ADT, 6.7% had metastasis, 3.3% reached castration resistant status, and 3.3% died of prostate cancer. On the whole, 48.9% patients required adjuvant therapy. For patients with N1 disease with early ADT given, 12.5% had castration resistance but none of them died at a median follow-up of 10 years.

Conclusions: Radical prostatectomy with adjuvant therapy provided good cancer control and long-term survival in high-risk prostate cancers.

Source of Funding: None

 
Listen to an interview with Peter Ka-Fung Chiu, one of the authors of this study.

Presented by Peter Ka-Fung Chiu, Kim W.M. Lee, 
Simon S.M. Hou, Chi-Fai Ng at the 32nd World Congress of Endourology & SWL - September 3 - 7, 2014 - Taipei, Taiwan

Division of Urology, Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong

 

 

@UroToday
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe

Calendar
Upcoming educational events
January 24-27, 2019 / The Westin Riverfront at Beaver Creek
29th Annual International Prostate Cancer Update (IPCU)
February 1, 2019 / Thomas Jefferson University, Jefferson Alumni Hall, 1020 Locust Street, Philadelphia, PA
2nd Annual Jefferson Urology Symposium: Emerging Technologies for the Treatment of BPH